Effects of an SGLT Inhibitor on the Production, Toxicity, and Elimination of Gut-Derived Uremic Toxins: A Call for Additional Evidence

Uraemic solutes as therapeutic targets in CKD-associated cardiovascular disease

(2021) Jonathan D. Ravid et al.   Nature Reviews Nephrology

SGLT‐1‐specific inhibition ameliorates renal failure and alters the gut microbial community in mice with adenine‐induced renal failure

(2021) Hsin‐Jung Ho et al.   Physiological Reports

A Cardiovascular Disease-Linked Gut Microbial Metabolite Acts via Adrenergic Receptors

(2020) Ina Nemet et al.   CELL

Overview of the Clinical Pharmacology of Ertugliflozin, a Novel Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitor

(2020) Daryl J. Fediuk et al.   CLINICAL PHARMACOKINETICS

Dietary Fiber Protects against Diabetic Nephropathy through Short-Chain Fatty Acid–Mediated Activation of G Protein–Coupled Receptors GPR43 and GPR109A

(2020) Yan Jun Li et al.   JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY

Comparative Pharmacokinetics and Pharmacodynamics of a Novel Sodium-Glucose Cotransporter 2 Inhibitor, DWP16001, with Dapagliflozin and Ipragliflozin

(2020) Min-Koo Choi et al.   Pharmaceutics

Drugs Commonly Applied to Kidney Patients May Compromise Renal Tubular Uremic Toxins Excretion

(2020) Silvia M. Mihaila et al.   Toxins

Relative and Absolute Risk Reductions in Cardiovascular and Kidney Outcomes With Canagliflozin Across KDIGO Risk Categories: Findings From the CANVAS Program

(2020) Brendon L. Neuen et al.   AMERICAN JOURNAL OF KIDNEY DISEASES

Dapagliflozin in Patients with Chronic Kidney Disease

(2020) Hiddo J.L. Heerspink et al.   NEW ENGLAND JOURNAL OF MEDICINE

Association of SGLT2 Inhibitors With Cardiovascular and Kidney Outcomes in Patients With Type 2 Diabetes

(2020) Darren K. McGuire et al.   JAMA Cardiology

Gut microbiota-derived metabolites as central regulators in metabolic disorders

(2020) Allison Agus et al.   GUT

Empagliflozin restores chronic kidney disease-induced impairment of endothelial regulation of cardiomyocyte relaxation and contraction

(2020) Rio P. Juni et al.   KIDNEY INTERNATIONAL

Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease

(2020) Deepak L. Bhatt et al.   NEW ENGLAND JOURNAL OF MEDICINE

SGLT2 inhibitors: expanding their Empire beyond diabetes

(2020) Marcel H A Muskiet et al.   Lancet Diabetes & Endocrinology

Sotagliflozin, the first dual SGLT inhibitor: current outlook and perspectives

(2019) Chiara Maria Assunta Cefalo et al.   Cardiovascular Diabetology

Pharmacokinetic and Pharmacodynamic Modeling for Renal Function Dependent Urinary Glucose Excretion Effect of Ipragliflozin, a Selective Sodium Glucose Cotransporter 2 (SGLT2) Inhibitor, Both in Healthy Subjects and Patients with Type 2 Diabetes Mellitus

(2019) Masako Saito et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Gut microbiome-derived phenyl sulfate contributes to albuminuria in diabetic kidney disease

(2019) Koichi Kikuchi et al.   Nature Communications

Canagliflozin and Cardiovascular and Renal Outcomes in Type 2 Diabetes and Chronic Kidney Disease in Primary and Secondary Cardiovascular Prevention Groups: Results from the Randomized CREDENCE Trial

(2019) Kenneth W. Mahaffey et al.   CIRCULATION

Inulin-type fructan intervention restricts the increase in gut microbiome–generated indole in patients with peritoneal dialysis: a randomized crossover study

(2019) Li Li et al.   AMERICAN JOURNAL OF CLINICAL NUTRITION

Development of SGLT1 and SGLT2 inhibitors

(2018) Timo Rieg et al.   DIABETOLOGIA

Shifts on Gut Microbiota Associated to Mediterranean Diet Adherence and Specific Dietary Intakes on General Adult Population

(2018) Izaskun Garcia-Mantrana et al.   Frontiers in Microbiology

Microbiota-Derived Phenylacetylglutamine Associates with Overall Mortality and Cardiovascular Disease in Patients with CKD

(2016) R. Poesen et al.   JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY

Structural and functional significance of water permeation through cotransporters

(2016) Thomas Zeuthen et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Pharmacokinetics, Pharmacodynamics and Clinical Use of SGLT2 Inhibitors in Patients with Type 2 Diabetes Mellitus and Chronic Kidney Disease

(2015) André J. Scheen   CLINICAL PHARMACOKINETICS

Clinical Pharmacokinetic, Pharmacodynamic, and Drug–Drug Interaction Profile of Canagliflozin, a Sodium-Glucose Co-transporter 2 Inhibitor

(2015) Damayanthi Devineni et al.   CLINICAL PHARMACOKINETICS

High-level adherence to a Mediterranean diet beneficially impacts the gut microbiota and associated metabolome

(2015) Francesca De Filippis et al.   GUT

SGLT2 inhibitor lowers serum uric acid through alteration of uric acid transport activity in renal tubule by increased glycosuria

(2014) Yukihiro Chino et al.   BIOPHARMACEUTICS & DRUG DISPOSITION

Effect of Increasing Dietary Fiber on Plasma Levels of Colon-Derived Solutes in Hemodialysis Patients

(2014) T. L. Sirich et al.   Clinical Journal of the American Society of Nephrology

The Uremic Toxicity of Indoxyl Sulfate and p-Cresyl Sulfate: A Systematic Review

(2014) R. Vanholder et al.   JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY

Uremic solutes and risk of end-stage renal disease in type 2 diabetes: metabolomic study

(2014) Monika A. Niewczas et al.   KIDNEY INTERNATIONAL

The Kidney and Uremic Toxin Removal: Glomerulus or Tubule?

(2014) Rosalinde Masereeuw et al.   SEMINARS IN NEPHROLOGY

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Rising Doses of Empagliflozin in Patients with Type 2 Diabetes Mellitus

(2013) Tim Heise et al.   Diabetes Therapy

Discovery of Tofogliflozin, a Novel C-Arylglucoside with an O-Spiroketal Ring System, as a Highly Selective Sodium Glucose Cotransporter 2 (SGLT2) Inhibitor for the Treatment of Type 2 Diabetes

(2012) Yoshihito Ohtake et al.   JOURNAL OF MEDICINAL CHEMISTRY

Effect of Canagliflozin on Renal Threshold for Glucose, Glycemia, and Body Weight in Normal and Diabetic Animal Models

(2012) Yin Liang et al.   PLoS One

Empagliflozin, a novel selective sodium glucose cotransporter-2 (SGLT-2) inhibitor: characterisation and comparison with other SGLT-2 inhibitors

(2011) R. Grempler et al.   DIABETES OBESITY & METABOLISM

Discovery of a Clinical Candidate from the Structurally Unique Dioxa-bicyclo[3.2.1]octane Class of Sodium-Dependent Glucose Cotransporter 2 Inhibitors

(2011) Vincent Mascitti et al.   JOURNAL OF MEDICINAL CHEMISTRY

Uremic toxins originating from colonic microbial metabolism

(2009) Pieter Evenepoel et al.   KIDNEY INTERNATIONAL

p-Cresyl sulfate serum concentrations in haemodialysis patients are reduced by the prebiotic oligofructose-enriched inulin

(2009) B. K. I. Meijers et al.   NEPHROLOGY DIALYSIS TRANSPLANTATION